Compound glycyrrhizin protects against vancomycin-induced acute kidney injury: a cohort study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400094905

Enrollment

Unknown

Registered

2024-12-30

Start date

2025-01-01

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute kindey injury

Interventions

Vancomycin group:NA

Combination of vancomycin and compound glycyrrhizin group:NA

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (a) patients treated with vancomycin for anti-infective treatment (b) Compound glycyrrhizin preparation combined with vancomycin treatment. Compound glycyrrhizin preparations include diamine glycyrrhizin enteric-coated tablets, diamine glycyrrhizin enteric-coated capsules, compound monoammonium glycyrrhizin S injection, monoammonium cysteine sodium chloride injection, compound glycyrrhizin capsule, compound glycyrrhizin injection, magnesium isoglycyrrhizinate injection. (c) Vancomycin and compound glycyrrhizin preparations are used simultaneously for more than 48 hours.

Exclusion criteria

Exclusion criteria: (a) Stage 5 chronic kidney disease or regular dialysis, (b) renal transplant status or solitary kidney, (c) non-intravenous vancomycin, (d) Inadequate measurement of serum creatinine (SCr).

Design outcomes

Primary

Measure	Time frame
Serum creatinine;	—

Countries

China

Contacts

Public ContactKunming Pan

Zhongshan Hospital Fudan University

panxso@163.com+86 150 2662 9516

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026